At the same time, studies have found that CDK4/6 inhibitors inhibit the proliferation of Treg cells by inducing the secretion of IL‐29, IL‐28a and IL‐28b from senescent breast cancer cells, overcoming tumour immune evasion and enhancing anti‐tumour immunity.99 Here, CDK4 is linked to breast cancer.